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Abstract
Discrepancies in the prognosis of triple negative breast cancer exist between Caucasian and Asian populations. Yet, the
gene signature of triple negative breast cancer specifically for Asians has not become available. Therefore, the purpose of
this study is to construct a prediction model for recurrence of triple negative breast cancer in Taiwanese patients. Whole
genome expression profiling of breast cancers from 185 patients in Taiwan from 1995 to 2008 was performed, and the
results were compared to the previously published literature to detect differences between Asian and Western patients.
Pathway analysis and Cox proportional hazard models were applied to construct a prediction model for the recurrence of
triple negative breast cancer. Hierarchical cluster analysis showed that triple negative breast cancers from different races
were in separate sub-clusters but grouped in a bigger cluster. Two pathways, cAMP-mediated signaling and ephrin receptor
signaling, were significantly associated with the recurrence of triple negative breast cancer. After using stepwise model
selection from the combination of the initial filtered genes, we developed a prediction model based on the genes SLC22A23,
PRKAG3, DPEP3, MORC2, GRB7, and FAM43A. The model had 91.7% accuracy, 81.8% sensitivity, and 94.6% specificity under
leave-one-out support vector regression. In this study, we identified pathways related to triple negative breast cancer and
developed a model to predict its recurrence. These results could be used for assisting with clinical prognosis and warrant
further investigation into the possibility of targeted therapy of triple negative breast cancer in Taiwanese patients.
Citation: Chen LH, Kuo W-H, Tsai M-H, Chen P-C, Hsiao CK, et al. (2011) Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast
Cancer Patients in Taiwan. PLoS ONE 6(11): e28222. doi:10.1371/journal.pone.0028222
Editor: Wanjin Hong, Institute of Molecular and Cell Biology, Singapore
Received June 8, 2011; Accepted November 3, 2011; Published November 29, 2011
Copyright:  2011 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Financial support provided by the National Science Council, Taiwan (Grant No. 97-2314-B-002-154-MY3) and the Center of Genomic Medicine, National
Taiwan University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: llai@ntu.edu.tw (L-CL); kingjen@ntu.edu.tw (K-JC)
. These authors contributed equally to this work.
Introduction
Breast cancer is the most common female solid tumor, and is
among the top five leading causes of cancer-related death among
Taiwanese women [1]. It is a heterogeneous disease that
encompasses a spectrum of distinct phenotypes with disparate
histopathological, clinical and molecular features. It can be
classified into different subtypes on the basis of cellular
morphology and the presence of several receptors, i.e., estrogen
receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (ERBB2/HER2). Understanding its
pathophysiology has led to the development of targeted therapies
and improvement in clinical outcomes for patients. For example,
for hormone receptor-positive breast cancer patients, hormone
therapy has been approved as an adjuvant therapy, while for
HER2-positive breast cancer, targeted therapy can be effective.
However, one type of breast cancer, triple-negative breast cancer
(TNBC), does not express ER, PR, and HER2. The signaling
pathways and genes involved in TNBC have been studied for
years, but there has been no significant progress toward adjuvant
therapy. The prognosis of breast cancer is highly correlated with
its subtype, and without adjuvant therapy, TNBC has the worst
prognosis and of any breast cancer subtype [2–4]. The treatment
of TNBC, therefore, remains a difficult challenge in clinical
practice.
TNBC comprises approximately 10–16% of breast cancer cases
[2,5]. The main characteristic of TNBC is that it frequently affects
younger patients, occurring predominantly in premenopausal
women [6,7]. The molecular mechanisms of TNBC still remain
unclear, although their association with poor prognosis is thought
to be due to aggressive biology and resistance to presently available
endocrine therapies, agents targeting HER2 pathways, and
standard cytotoxic chemotherapies.
Recent evidence supports the idea that the epidemiology and
prognosis of breast cancer differs between races, most likely due to
different genetic compositions [5,8,9]. Discrepancies in the
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Taiwan were specifically noted [2]. However, few studies have
investigated the genetic differences between breast cancers from
Caucasian and Asian populations, let alone lower incidence of
TNBC than other subtypes.
Since the advent of microarray chips, the mechanisms of breast
cancer have been studied intensively, such that the subtype of
breast cancer can be identified by its gene expression profile [10].
Breast cancer gene expression profiles have been identified across
different microarray platforms by different research groups [11].
Several prediction models have been proposed, such as the 70-
gene profile, two-gene ratio, or singular value decomposition, to
predict lymph node metastasis [12–18]. The 70-gene profile for
disease outcome prediction was a pioneering study, and has since
been verified in several other studies [13]. It not only predicts
outcomes effectively, but also outperforms other methods based on
clinical parameters. Other studies using microarray gene expres-
sion profiles for clinical outcome prediction also provide
satisfactory results [12,14–17]. The use of microarray chips has
proven to be a useful strategy to detect candidate genes and
pathways involved in tumor progression.
The aforementioned success, however, has not been observed
for TNBC patients, especially in the prediction of recurrence.
Difficulties have arisen because of its relatively complex etiology,
and because of the deficiency of TNBC samples. Yet, knowledge
of the genes associated with recurrence of TNBC is desperately
needed for designing prediction models and treatment strategies,
possibly including targeted therapy.
This study used a Cox proportional hazards model to predict
TNBC recurrence in a Taiwanese population. We compared the
expression profiles of breast cancers from 185 Taiwanese patients
to profiles from a Caucasian population [16]. The microarray
results revealed differences in TNBC gene expression profiles in
different ethnic groups. Pathway analysis showed that several
canonical pathways, such as cAMP-mediated signaling and ephrin
receptor signaling, are activated in association with recurrence in
TNBC. Furthermore, six prognostic genes were identified for
predicting the risk of recurrence of TNBC in Taiwanese patients.
Materials and Methods
Ethnic Statement
Written informed consent was acquired from all patients and/or
guardians for the use of their tissue samples. This study was
reviewed and approved by Research Ethics Committee of
National Taiwan University Hospital.
Sample collection
One hundred and eighty-five female breast cancer samples were
collected at the National Taiwan University Hospital between
1995 and 2008. Breast tissue specimens were immediately snap-
frozen in liquid N2 and stored at 280uC for RNA extraction.
Similar numbers of samples in each subtype were included in this
study; therefore the percentage of each subtype was not
compatible with its prevalence.
Isolation and amplification of total RNA for gene
expression profiling
Total RNAs from the tissue specimens were extracted by
TRIzolH reagent (Invitrogen, Carlsbad, CA) and subsequently
purified with RNeasyH Mini Kits (Qiagen) according to the
manufacturer’s instructions. The integrity of RNA was determined
using a 2100 BioAnalyzer (Agilent Technologies). RNA that had
an RNA Integrity Number (RIN) .7.0 was used for microarray
analysis. Total RNA (500 ng) was first reverse transcribed into
cDNA by incorporating a T7 oligo-dT promoter primer prior to
the generation of fluorescent Cy5-labeled cRNA using an Agilent
Quick Amp Labeling Kit (Agilent Technologies). The labeled
cRNA was purified using an RNeasy Mini Kit (Qiagen) and
quantified using a NanoDrop ND-1000 instrument (Thermo
Fisher Scientific). The common reference design was used where
Universal Human Reference RNA (Stratagene, La Jolla, CA) was
hybridized to every sample. Cy3- (reference) and Cy5-labeled
(sample) cRNAs were co-hybridized to the Agilent Human 1Av2
oligo microarray using a Gene Expression Hybridization Kit
(Agilent Technologies). All procedures were performed based on
the manufacturer’s protocols. The glass slides were scanned using
an Agilent G2565BA microarray scanner. Raw data were
collected using the Feature Extraction software (Agilent Technol-
ogies) and normalized by applying the rank consistency LOWESS
normalization. Microarray data of this study are MIAME
compliant, and have been submitted to the MIAME compliant
GEO (Gene Expression Omnibus) database (accession number
GSE33095).
Data mining and statistical analysis
In order to investigate whether discrepancies exist in gene
expression profiles of breast cancer between Caucasian and Asian
populations, our data were combined with another microarray
data with the same platform and analyzed together [16]. In order
to make these two datasets comparable, the microarray data were
processed as follows. First, due to the difference in versions of
Agilent chips, only 8843 genes existing in both datasets were used
for further analysis. Secondly, because the reference sample of van
de Vijver’s data was mixed samples of all breast cancer, not
Universal Human Reference RNA, the expression value of each
gene in our dataset was further normalized by its corresponding
mean. Thirdly, differentially expressed genes were selected if they
had a §4-fold change as compared to the median based on at
least 15 samples. Fourthly, because the HER2 and PR staining
status were not available, the expression levels of ERBB2 and PGR
were used for representing HER2 and PR status. After the HER2
and PR status was determined, the similarity of gene expression
profiles between samples was assessed by average-linkage hierar-
chical clustering using Euclidean distance. The Database for
Annotation, Visualization and Integrated Discovery (DAVID) was
applied for significant genes differentiated by two-way ANOVA
[19,20]. Lastly, in order to examine their expression patterns in
Asian populations, a list of basal-like characteristic genes in
Caucasians was collected from the published literature
[10,11,21,22].
Construction of the recurrence model for TNBC and
pathway analysis
Among the 185 Taiwanese breast cancer patients, 51 were
diagnosed with TNBC. After excluding those with distant
metastasis upon diagnosis (n=3), 48 patients with non-terminal
stage TNBC were included for constructing the recurrence model.
The time interval of recurrence was defined as the period between
the surgery date and the date when recurrence was detected. In
order to investigate the risk of recurrence among TNBC subjects, a
Cox proportional hazards ratio model was applied to each gene.
The coefficients in a Cox regression related to hazard. A positive
coefficient in a Cox regression model indicated high risk of
recurrence as expression level of gene increases; whereas a
negative coefficient indicated low risk of recurrence as expression
level of gene increases. Genes whose expression levels were
associated with the time to recurrence of TNBC were selected at
Genes for Predicting Recurrent Risk in TNBC
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(IPA; Ingenuity Systems Inc., Redwood City, USA). Furthermore,
in order to select the most appropriate model for recurrence
prediction, the Akaike information criterion (AIC) and Bayesian
information criterion (BIC), measures of the goodness of fit of an
estimated statistical model, were applied. Lastly, we chose the
predictive model with the best score of model selection, and
examined whether the model contained genes related to breast
cancer.
Cross-validation of the recurrence model by leave-one-
out support vector regression
The support vector machine, a well-developed machine
learning method, was used to train the recurrence model and
cross-validate the results by leave-one-out. Briefly, support vector
regression was done at two steps: first, training the recurrence
model with current data; second, applying on a new dataset to
predict the outcomes. The outcomes were cross-validated by using
a single observation from the original sample as the validation
data, and the remaining observations as the training data. This
was repeated such that each observation in the sample was used
once as the validation data.
Results
Clinical characteristics of samples
The clinical characteristics of samples used in this study are
summarized in Table 1. Based on the result of immunohisto-
chemistry (IHC) stains of ER, PR and HER2, there were 49
luminal A, 31 luminal B, 35 HER2, 51 triple negative, and 19
other types. All these patients received surgery, adequate
chemotherapy and adjuvant therapy. Twenty-four of them were
grade 1, 77 grade 2, and 71 grade 3. Among these patients, 33
were diagnosed as stage I, 84 as stage II, 58 as stage III, and 10 as
stage IV. The median follow-up time was 4.15 years; 40 patients
relapsed after their first surgery, and the rest (145 patients) did not
experience recurrence by the end of this study.
Classification of tumor subtypes by gene expression
profiling
In order to investigate the differences in the expression profiles
of breast cancers from Caucasian and Asian populations, we
compared our microarray data with that of van de Vijver et al.
[16]. To make these two datasets comparable, the data were
processed as described in Materials and Methods. There were 506
differentially expressed genes, defined as a §4-fold change as
compared to the median of at least 15 samples. Average-linkage
hierarchical clustering using Euclidean distance was applied to the
normalized expression values to evaluate the similarity of gene
expression profiles between Caucasian and Asian populations. As
shown in Figure 1A, TNBC samples in van de Vijver’s study (blue
bars) and those in this study (yellow bars) are in separate
subclusters, but most of the TNBC samples were grouped in the
bigger cluster (pink line). Although 29.8% of TNBC samples were
scattered outside of the major group, these results still indicated
that the characteristics of gene expression cannot only be used to
distinguish TNBC from other cancer types, but also that
differences in the expression profile of TNBC do exist between
different ethnic groups. To emphasize the differences between the
two ethnic groups, the dendrogram and heatmap were expanded
Table 1. Summary statistics for patient profile (n=185).
Clinical characteristics Sample size (n) Percentage Sample size of TNBC (n) Percentage of TNBC
Histological Types
Luminal A 49 26%
Luminal B 31 17%
HER2 35 19%
Triple negative 51 28%
Others 19 10%
Grade
Grade 1 24 13% 0 0%
Grade 2 77 42% 15 29%
Grade 3 71 38% 32 63%
Missing data 13 7% 4 8%
Stage
Stage I 33 18% 12 24%
Stage IIA 42 23% 18 35%
Stage IIB 42 23% 7 14%
Stage IIIA 29 16% 4 8%
Stage IIIB 3 2% 1 2%
Stage IIIC 26 14% 6 12%
Stage IV 10 5% 3 6%
Recurrence
Yes 40 22% 14 27%
No 145 78% 37 73%
doi:10.1371/journal.pone.0028222.t001
Genes for Predicting Recurrent Risk in TNBC
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samples (Figure 1B). Similar procedures applied on another
dataset GSE18229 (Figure S1), both results showed apparent
differences between different races.
Next, statistical analysis using two-way ANOVA revealed that
66 genes had differential expression between the different races,
but not across cancer subtypes. Pathway analysis using DAVID
also revealed that these genes were involved in drug metabolism of
fluorouracil and retinol metabolism, indicating that these path-
ways could account for the differences in ethnic groups but not in
breast cancer subtypes (Table S1) [19,20]. Furthermore, we
collected 62 reported basal-like genes (Table S2) from Western
populations, and examined their expression patterns in our
samples [10,11,21,22]. As shown in Figure 1C, no obvious up-
regulation of these basal-like genes was observed in our TN
samples, but they were all up-regulated in the samples from
Western populations [10,11,21,22]. These results showed that the
expression profiles of TNBC are different in Caucasians and
Asians.
Pathway analysis and prediction model for recurrence
Since we knew that differences exist between Western and
Eastern populations, we then focused on identifying genes
associated with recurrence in our TNBC samples. There were
51 TNBC samples, and 48 of them were used for constructing a
recurrence model because 3 TNBC patients had distant metastasis
upon diagnosis. The time interval of recurrence was defined as the
period between the surgery date and the date when recurrence was
detected. In order to investigate the hazard of recurrence among
TNBC subjects, a Cox proportional hazards model was construct-
ed for each gene. There were 391 genes whose expression levels
were significantly (P,0.005) associated with recurrence time in
TNBC.
To further investigate which pathways were active in genes
associated with recurrence of TNBC, Ingenuity Pathway Analysis
was performed. Table 2 lists the canonical pathways in which
genes associated with recurrence of TNBC were significantly
enriched. The top two pathways were cAMP-mediated signaling
and ephrin receptor signaling.
Next, in order to establish an appropriate model to predict the
probability of recurrence of TNBC, Cox proportional hazards
models using different combinations of genes were applied.
Considering that the total number of genes at P,0.005 level
was enormous, genes at P,0.0005 level were used for establishing
the prediction model. There were 35 genes with P values,0.0005
(Table 3).
The recurrence hazards of all possible combinations of 35 genes
(34.3 billion combinations) were calculated using Cox proportional
hazards models. The Akaike information criterion (AIC) was used
to select the most appropriate model for recurrence prediction.
The model with the smallest AIC was considered the best of 34.3
billion combinations. The top 10 best-fitted models are listed in
Table 4. The first model, which contains SLC22A23, PRKAG3,
DPEP3, MORC2, GRB7, and FAM43A, has not only the smallest
AIC but also the smallest Bayesian information criterion (BIC).
This model was further cross-validated by leave-one-out support
vector regression, during which 91.7% accuracy with 81.8%
sensitivity and 94.6% specificity was achieved. These results
suggest that the six-gene model presented can be used to predict
the recurrence of TNBC in Taiwanese patients.
Table 2. Canonical pathways in which genes were associated with recurrence of TNBC.
Ingenuity Canonical Pathways 2log(P-value) Gene No. (%*) Genes
#
cAMP-mediated Signaling 3.70 11 (6.83%) AKAP12, GNAI2, AKAP13, ADCY5, MAPK3, PDE1B, PRKAR1B, DUSP4,
RAPGEF3, AKAP1, ATF2
Ephrin Receptor Signaling 3.33 11 (5.61%) GNAI2, GRIN1, EPHA8, MAPK3, GRIN2D, ABL1, HRAS, ITGA3, PGF,
EFNA1, ATF2
Pancreatic Adenocarcinoma Signaling 3.09 8 (6.90%) TGFB1, MAPK3, ABL1, HBEGF, CDKN1B, E2F3, PGF, BCL2
Amyotrophic Lateral Sclerosis Signaling 2.71 7 (6.25%) GRIN1, CACNA1E, GRIN2D, RAB5C, CAPN7, PGF, BCL2
Cardiac b-adrenergic Signaling 2.66 8 (5.63%) AKAP12, AKAP13, CACNA1E, ADCY5, ADRBK2, PDE1B, PRKAR1B,
AKAP1
Chronic Myeloid Leukemia Signaling 2.66 7 (6.67%) TGFB1, MAPK3, HDAC7, ABL1, HRAS, CDKN1B, E2F3
Circadian Rhythm Signaling 2.56 4 (1.14%) PER1, GRIN1, GRIN2D, ATF2
Synaptic Long Term Potentiation 2.44 7 (6.19%) GRIN1, MAPK3, GRIN2D, PRKAR1B, HRAS, RAPGEF3, ATF2
Cell Cycle: G1/S Checkpoint Regulation 2.37 5 (8.47%) TGFB1, HDAC7, ABL1, CDKN1B, E2F3
Prostate Cancer Signaling 2.36 6 (6.25%) MAPK3, ABL1, HRAS, CDKN1B, BCL2, ATF2
*Percentage of the number of differentially expressed genes in each canonical pathway.
#Differentially expressed genes in each canonical pathway.
doi:10.1371/journal.pone.0028222.t002
Figure 1. Gene expression profiles of Triple negative breast cancer differ between Caucasian and Asian populations in Taiwan. A.
Hierarchical clustering of breast cancer samples from van de Vijver’s study (n=295) and this study (n=185). Basal-like breast cancer samples in van de
Vijver’s study are marked with blue bars and those in this study are marked with yellow bars. The criterion of differentially expressed genes (n=506)
was that, among at least 15 samples, the gene had a §4-fold change as compared to the median. Expression values of genes were normalized by
their respective means. Red indicates that the expression values were higher than average; green represents that the values were lower than average.
B. Hierarchical clustering of basal-like breast cancer samples from van de Vijver’s study (n=49; blue) and this study (n=64; yellow). C. The expression
patterns of well-known basal-like genes in this study. The basal-like genes (n=62) were obtained from previous studies [10,11,21,22]. The triple
negative (TN) samples are indicated with a yellow bar and the non-TN samples are indicated with a gray bar.
doi:10.1371/journal.pone.0028222.g001
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In this study we have shown that genetic profiling can be used
not only to distinguish TNBC from other breast cancer types, but
also to differentiate TNBCs derived from different ethnic groups.
Using Cox proportional hazards models, genes and pathways that
were associated with the recurrence of TNBC were identified.
Moreover, we identified 6 genes (SLC22A23, PRKAG3, DPEP3,
MORC2, GRB7, and FAM43A) which could be used to predict the
recurrence of TNBC with 91.7% accuracy. These results could be
used for assisting clinical prognosis and further investigation into
targeted therapy of TNBC in Taiwanese.
The epidemiology and prognosis of breast cancer between
different races were reported to be different [5,8,9]. Our results are
the first to show the differences in genetic profiles of TNBC
samples between Western and Asian populations in Taiwan.
Furthermore, some of the most well-known genes for basal-like
breast cancer, such as keratin 5 and keratin 17, were not even
significantly different between our TN and non-TN samples [23].
These results indicate that biomarkers cannot be blindly used in
different ethnic groups, and emphasize the importance of
establishing biomarkers for TNBC in Asian populations.
Also, pathway analysis showed that 66 genes with differential
expression patterns between races were involved in drug
metabolism of fluorouracil and retinol metabolism. This finding
may explain why some chemotherapy drugs have different effects
on different ethnic groups. For example, several studies of
Capecitabine, a prodrug of fluorouracil used for treating colorectal
cancers, have shown different effects in different ethnic
groups[24,25]. One study demonstrated that thymidylate syn-
thase, an important target for fluorouracil, may be expressed
differently between Asian and Caucasian patients [24]. In
addition, the hand-and-foot syndrome resulting from Capecita-
bine-associated toxicity may also display various patterns with
different ethnic populations [25]. The other pathway that these
genes were involved in was retinol metabolism. Since retinoic acid
and retinol can enhance pigmentation of skin [26], it is not
surprising that there is significantly different expression profiling
between Asian and Caucasian populations, because the skin colors
are different.
In our pilot study, we found that lymphovascular invasion,
lymph node status, grade, nuclear pleomorphism, and tumor size
were not associated with recurrence, but that age was mildly
significantly associated (P=0.0436) with recurrence. Therefore,
we turned to gene expression to predict the recurrence of TNBC.
Using Cox proportional hazards models, we identified 391 genes
whose expression levels were significantly (P,0.005) associated
with the recurrence time in TNBC. These genes were enriched in
several pathways including cAMP-mediated signaling and ephrin
receptor signaling. The ephrin receptor signaling pathway has
been recognized in many studies of its tumor suppression in breast
cancer[27,28]. Our study confirmed the previous results and
Table 4. The top 10 prediction models for the recurrence of TNBC.
No. Genes used in the Model AIC* BIC
1
1 SLC22A23(219.98)
#,PRKAG3(51.51),DPEP3(21.89), MORC2(2143.12),GRB7(141.32),FAM43A(167.24) 16.26 32.70
2 SLC22A23(212.24),PRKAG3(33.01),MORC2(288.76), GRB7(87.67),FAM43A(105.93),BCAM(0.52) 16.33 32.77
3 PRKAG3(33.07),MORC2(266.15),SP2(232.70), GRB7(48.66),FAM43A(57.79),BCAM(5.98) 17.09 33.54
4 MKRN2(2128.88),GRB7(47.29),LACRT(29.45), SPRR1A(62.98),BCAM(2110.68),TNFRSF4(41.51) 17.26 33.70
5 FFAR2(4.97),PRKAG3(10.68),PGF(212.70), MORC2(224.72),GRB7(18.91),FAM43A(26.48) 17.71 34.15
6 PRKAG3(24.00),MORC2(252.48),SP2(27.81), GRB7(47.24),FAM43A(49.48),LCE1D(20.97) 17.74 34.18
7 MKRN2(274.83),PRKAG3(52.61),GRB7(39.25), MAFK(261.19),SPRR1A(8.38),MRPS9(239.45) 17.77 34.21
8 MKRN2(283.22),MRPS5(235.24),PRKAG3(49.02), DPEP3(33.94),CCDC33(253.64),SPRR1A(24.23) 17.89 34.33
9 MKRN2(228.21),MORC2(215.71),GRB7(20.86), LACRT(8.55),SPRR1A(20.30),BCAM(225.95) 17.89 34.34
10 MKRN2(11.67),PRKAG3(46.49),PGF(210.40), MORC2(2120.16),GRB7(114.51),FAM43A(125.69) 18.12 34.57
#The coefficient of each gene in Cox proportional hazard regression is shown in parentheses. A positive coefficient in a Cox regression model indicated high risk of
recurrence as expression level of gene increases; whereas a negative coefficient indicated low risk of recurrence as expression level of gene increases.
*AIC: Akaike information criterion.
1BIC: Bayesian information criterion.
doi:10.1371/journal.pone.0028222.t004
Table 3. Genes whose expression levels were associated with
the time to recurrence of TNBC using Cox proportional
hazards regression.
Gene Hazard* P-value Gene Hazard P-value
FFAR2 2.78 7.08610
26 LACRT 2.00 3.20610
24
MKRN2 0.17 1.97610
25 CCDC33 3.23 3.36610
24
GPX3 2.47 7.84610
25 SPRR1A 2.49 3.48610
24
SCL22A23 2.84 1.22610
24 MGC16385 0.24 3.55610
24
INSM2 2.60 1.31610
24 YPEL3 3.43 3.59610
24
MRPS5 0.38 1.33610
24 EPHA8 2.08 3.75610
24
UFC1 0.23 1.43610
24 HAS3 2.89 3.76610
24
PRKAG3 2.85 1.81610
24 HBEGF 2.47 3.83610
24
PGF 4.30 1.81610
24 CHST7 3.34 3.89610
24
LPIN1 0.19 1.83610
24 MRPS9 0.27 3.99610
24
JUND 3.40 1.92610
24 BCAM 2.17 4.09610
24
DPEP3 2.40 2.11610
24 GPR157 2.65 4.19610
24
MORC2 0.33 2.27610
24 ZNF285 0.20 4.29610
24
SP2 3.89 2.39610
24 MYO3A 1.98 4.44610
24
GRB7 2.12 2.41610
24 LCE1D 2.30 4.53610
24
MAFK 3.02 2.78610
24 TNFRSF4 2.52 4.72610
24
FAM43A 5.40 2.87610
24 C11orf56 3.49 4.84610
24
EGFL7 3.58 3.12610
24
*Hazard of each gene is the exponent of coefficient in a Cox regression.
doi:10.1371/journal.pone.0028222.t003
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the recurrence of TNBC. Other pathways could also be associated
with the recurrence of TNBC, but further evaluation and studies
are required. Previous studies have suggested the PARP1 inhibitor
pathway for targeting TNBC, but it did not meet the significance
cut-off in our pathway analysis [5]. This might be explained by the
intrinsic differences between different races.
For developing the best model with the fewest genes, the Akaike
information criterion (AIC) was used to evaluate the goodness of fit
of the estimated combinations. After scrutinizing 34.3 billion of
possibilities, the best Cox proportional hazards model for
predicting the recurrence of TNBC contained the following 6
genes: SLC22A23, PRKAG3, DPEP3, MORC2, GRB7, and
FAM43A. Among these 6 genes, the function of SLC22A23 (solute
carrier family 22, member 23), FAM43A (family with sequence
similarity 43, member A), and DPEP3 (dipeptidase 3) remains
unclear. PRKAG3, the protein kinase, AMP-activated, gamma 3
non-catalytic subunit, may play a role in regulating the energy
metabolism of skeletal muscle [29,30]. MORC2 (MORC family
CW-type zinc finger 2) was over-expressed in breast cancer tissue
and in situ carcinoma as compared to adjacent normal breast
tissue. However, its function in breast cancer remains unknown
[31,32]. GRB7 (growth factor receptor-bound protein 7) could
interact with some receptor tyrosine kinases and signaling
molecules. Several studies have indicated that GRB7 had an
adverse prognostic effect on breast cancer outcomes and is
associated with up-regulation of GRB7 in breast cancer [32].
Because of the absence of sufficient clinical information from
previously published studies, such as ER, PR, and HER2 status
and the clinical outcomes of the patients, our data cannot be
validated using an independent dataset. Furthermore, since the
subjects in this study had different observation periods, the cross-
validation was focused on predicting the possibility of recurrence.
We cross-validated this model by using leave-one-out support
vector regression. The accuracy of this model was 91.7%, the
specificity for TNBC was 94.6%, and the sensitivity was 81.8% as
compared to an average accuracy of 13.6% from one million
permutations of any six-gene model. Yet, since the prediction
model was established based on the TNBC patients in Taiwan, it is
probably not applicable to Caucasian populations, since none of
the genes found in our 6-gene prediction model were implicated
by previous survival predictions determined in Caucasians using a
70-gene profile or a two-gene ratio [13,14].
Because of the rarity of TNBC, the sample size of our study is
small compared to other published studies. However, to our
knowledge, this study has the largest sample size for TNBC in
recent years. The presented 6-combination gene set, including
SLC22A23, PRKAG3, DPEP3, MORC2, GRB7, and FAM43A, along
with several significant pathways, might underlie the basic
mechanism of the recurrence of TNBC, and points out a new
avenue for further investigation.
Supporting Information
Figure S1 Gene expression profiles of Triple negative breast
cancer differ between Caucasian and Asian populations in Taiwan
using dataset GSE18229. A. Triple negative breast cancer samples
(marked by yellow: our samples and blue: western samples) were
clustered regardless of different data sources. B. Only triple
negative breast cancer samples were used in clustering (yellow: our
samples, blue: western samples).
(TIF)
Table S1 Enriched pathways of differential expression genes
between different races, but not in cancer subtypes, using DAVID.
(DOC)
Table S2 Gene list of basal-like associated genes from Western
populations.
(DOC)
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